US Wind Pulls Out of Wind Turbine Manufacturing Facility at Sparrows Point, Md.

The company relinquishes its lease to shipbuilder Anduril Industries amid continued delays besetting Ocean City wind project

US Wind, the company behind a proposed offshore wind development off the coast of Ocean City, no longer plans to develop components for wind turbines at Baltimore County’s Sparrows Point — at least not for now.

The Baltimore-based company turned over its lease at the Tradepoint Atlantic site in Sparrows Point to Anduril Industries, the shipbuilding company whose arrival was heralded on Tuesday by a visit from President Donald Trump (R).

It comes as US Wind’s only offshore wind project, planned for Ocean City’s coastline, continues to face legal headwinds and roadblocks from the Trump administration.

At the tail end of President Joe Biden’s (D) administration, the US Wind project received its last federal permit, but the town of Ocean City challenged it shortly thereafter. And after Trump’s inauguration, the federal government that once defended the permit permit for the project signaled its intent to revoke it, spurring a new round of legal wrangling.

In a statement issued Tuesday, US Wind CEO Jeff Grybowski said his company “jumped at the opportunity” to bring “near-term” jobs to the Sparrows Point site as US Wind faces delays. The site will be taken over by Anduril, which plans to invest $3.7 billion at the former home of Bethlehem Steel to construct a new shipbuilding facility, Arsenal-2, that is expected to bring an estimated 3,100 permanent new jobs to Maryland.

“Our offshore wind plans, like many other similar projects in the U.S., are delayed due to legal disputes and uncertainty created by federal agencies. So, we are shifting our focus to helping Anduril build a state-of-the-art manufacturing facility at Sparrows Point,” Grybowski’s statement said. “This new development ensures that job creation and economic development can proceed apace at [Tradepoint].”

The facility at Tradepoint had been expected to fabricate steel components for wind turbines, including towers and monopiles, and create hundreds of manufacturing jobs. Last year, the Trump administration pulled back $47.4 million in grant funding that had been awarded during the Biden administration for the steel facility, called Sparrows Point Steel, but US Wind said at the time that it planned to move forward with the steel fabrication site anyway.

In a statement on Wednesday, Rebecca Rehr, the director of climate policy and justice at the Maryland League of Conservation Voters, bemoaned the news about Sparrows Point Steel, calling it another negative effect of Trump administration policies on clean-energy companies.

“Maryland faces rising energy demand and electricity bills. We have been consistently disappointed that the Trump administration doesn’t see the value across the supply chain for the clean energy industry, and continues to single out wind when wind is working,” Rehr said.

“We are seeing job and growth opportunities across clean energy sectors, yet this administration continues to block these projects, which are the fastest and cheapest to deploy,” her statement said.

Liz Burdock, president and CEO of Oceantic Network, a trade organization for the offshore wind industry, said in a statement that Tuesday’s US Wind announcement highlights that “many of the companies that serve offshore energy can deliver essential capabilities to a host of other ocean-based sectors.”

“Mobilizing our existing supply chain means helping those businesses find their next customer while continuing our work to advance homegrown offshore energy,” Burdock said.

Source

Source link

Taiwan-based Gudeng Aerospace opens first US manufacturing facility in Glendale

GLENDALE, AZ — Arizona’s semiconductor boom is creating new demand, and not just for massive chip factories, but for the specialized companies that keep them running.

On Tuesday, Taiwan-based Gudeng Precision Industrial celebrated the grand opening of Gudeng Aerospace, a new facility in Glendale that will manufacture critical semiconductor and aerospace components. It is part of a growing push to move more of that supply chain out of overseas shipping and into the West Valley.

Why Glendale

The Glendale plant is the company’s first in the United States. Gudeng Precision Industrial, the parent company, is known in the semiconductor industry and also does aerospace work. It already operates two factories in Taiwan.

General Manager Darren Chung said Arizona sits where the two industries meet, and that Glendale puts the company within driving distance of its aerospace and semiconductor customers.

“Arizona is the intersection between semiconductor and aerospace,” Chung said. “In Glendale, we have a perfect spot that we can drive to all of our aerospace customers and our semiconductor customers.”

Chung also pointed to the climate. Precision manufacturing depends on steady temperatures and very low humidity, and he said Arizona’s many sunny days help keep conditions constant.

Hiring

The company hopes to hire 30 to 35 people over the next two years. It is looking for high-skilled technicians, CNC machinists, machine operators and electricians, as well as people with a logic or inspection background for quality control.

All of the work will be hands-on manufacturing at the Glendale site, Chung said, not service work. Employees from Taiwan will come to Glendale to help get the plant started and train local hires.

Jobs are posted on LinkedIn and Indeed. Chung said people with a manufacturing background can also visit the Glendale shop in person.

Training the workforce

Glendale Vice Mayor Ray Malnar said the machines are assembled in Taiwan and shipped to the U.S., so they may differ from equipment commonly used here. He said that makes cooperation with local schools important, pointing to West-MEC and the community college system, which offer fast certificate programs.

“That training is going to be absolutely incredible for the workforce development within the entire region,” Malnar said.

A flagship for the region

Malnar called Gudeng a flagship business that could attract others to Arizona.

“There’s going to be many other businesses that they are associated with that will be coming to Arizona,” he said. “So it’s going to be a real boom for Arizona.”

Chung said both the aerospace and semiconductor industries are in what he called a “super cycle,” driven by demand for air travel and newer chips. He said the Airbus A350 he flew to the U.S. on has components made in Taiwan, and that the company’s goal is to build such parts in the United States.

“Our target is safety first,” Chung said.

This story was reported on-air by a journalist and has been converted to this platform with the assistance of AI. Our editorial team verifies all reporting on all platforms for fairness and accuracy.

Source link

Alvotech Wins FDA Approval to Expand U.S. Manufacturing Capacity for SIMLANDI at Reykjavik Facility

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland (October 5, 2026)

– Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company’s Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site.

“This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility,” said Lisa Graver, Chief Executive Officer of Alvotech. “The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.”

The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech’s manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations.

The approval follows the FDA’s July 2026 closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification. Alvotech therefore expects the FDA to be able to take action on other pending applications associated with the facility according to their respective goal dates. These include BLAs for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), AVT03, Alvotech’s proposed biosimilar to Prolia® and Xgeva® (denosumab) and AVT16/AVT80, Alvotech’s proposed biosimilars to Entyvio® (vedolizumab). Each application remains subject to the FDA’s individual review and regulatory decision.

About AVT02 / SIMLANDI® (adalimumab-ryvk)

AVT02 is a monoclonal antibody approved as a biosimilar to Humira® (adalimumab) in more than 50 countries globally, including the United States, Europe, Canada and Australia. It is currently marketed in the U.S. as SIMLANDI® and under private label, in Europe as HUKYNDRA®, in Canada as SIMLANDI® and in Australia as ADALACIP®. Teva Pharmaceuticals is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI® in the United States, while Alvotech is responsible for development and manufacturing.

For further information, contact:

Media

Benedikt Stefansson

Sarah MacLeod


[email protected]

Investors

Dr. Balaji V Prasad

Benedikt Stefansson

Mikaela Vilchez


[email protected]

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our

website

or follow us on social media on

LinkedIn

,

Facebook

,

Instagram

, and

YouTube

.

Use of trademarks

Third party trademarks are the property of their respective owners.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Source link

‘Significant milestone’ as York firm launches US manufacturing facility

Published 25th Sep 2026, 11:31 BST

Updated 25th Sep 2026, 11:31 BST

Launched as part of the company’s plans to expand in the region, the new manufacturing hub is located in the company’s site at University Research Park in Madison, Wisconsin.

The firm said the new manufacturing facility represents a “significant step forward” for its US operations, providing it with the “infrastructure and capacity to expand its US footprint and respond to growing demand”.

It comes after Abingdon first established a presence in Wisconsin in April of 2025, opening a research lab and commercial office.

Dr Chris Hand, executive chairman of Abingdon Health.

Speaking to The Yorkshire Post in March, Dr Chris Hand, executive chairman of Abingdon Health, said the choice to expand in the region had been driven by a demand from customers for “made in the USA solutions”.

The company raised £3.2m in October of last year to support the expansion.

Speaking on the opening of the new US facility, Chris Yates, president of Abingdon Health USA and chief commercial officer of the firm’s UK entity, said: “The opening of our Madison manufacturing hub is a significant milestone for Abingdon Health USA that enables us to offer a more comprehensive and integrated “end to end” CDMO solution for our US customers, paving the way for continued growth in the biggest med-tech market in the world.”

Abingdon Health develops and manufactures lateral flow tests, used to identify various illnesses and conditions. The company earlier this year launched a “world first” blood test designed to enable paramedics to more quickly identify strokes.

An official ribbon-cutting event for the firm’s new US site was attended by Congressman Mark Pocan, representing Wisconsin’s 2nd Congressional District, as well as Madison Mayor Satya Rhodes-Conway, WEDC Secretary John Miller, and other representatives from the Wisconsin State Legislature.

Mr Yates added: “We were delighted to welcome Representative Mark Pocan, Mayor Satya Rhodes-Conway, WEDC Secretary John Miller and other legislative and industry leaders to the ribbon-cutting ceremony.

“Their support throughout our journey is recognition of the importance of high-quality, domestic diagnostics manufacturing for the United States as well our investment in Madison and its community.”

As part of its expansion, Abingdon also recently listed on the OTCQB Venture Market in the US, trading under the abbreviation ABDXF.

In a trading update issued in July, Abingdon said its revenues had grown by more than 30 per cent – with further increases expected.

Updating investors on the financial year to the end of June 2026, the firm hailed strong growth in the second half of the financial year, with total revenue for the full year expected to reach £11.3m – 31 per cent on the £8.6m recorded 12 months before.

The company said there was a 63 per cent increase in revenue during the second half of the year compared to the first six months.

Source link

Eli Lilly Breaks Ground On $6.5 Billion Houston Manufacturing Facility

Eli Lilly and Company has broken ground on a $6.5 billion manufacturing facility in Houston, Texas, marking another milestone in the pharmaceutical company’s $50 billion initiative to expand domestic medicine production. The facility is one of 10 U.S. manufacturing sites Lilly has announced since 2020 and will produce active pharmaceutical ingredients (APIs) for Foundayo (orforglipron), the company’s first synthetic oral GLP-1 medicine, alongside other small-molecule medicines and advanced therapeutics.

The project is expected to create more than 600 high-wage permanent jobs and approximately 4,000 construction jobs. Permanent positions will include engineers, scientists, operations personnel, and laboratory technicians. Lilly has begun recruiting employees in the Houston area as it prepares to build and operate the new manufacturing complex.

The Houston facility will be Lilly’s fifth U.S. manufacturing location dedicated to producing active pharmaceutical ingredients among the sites announced since 2020. The investment is part of the company’s broader strategy to bring pharmaceutical manufacturing back to the United States, strengthen domestic supply chains, and expand production capacity to meet growing demand for its medicines in the United States and international markets.

One of the facility’s primary products will be Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist approved in the United States for weight management in adults with obesity or adults with overweight and a weight-related condition. Unlike peptide-based GLP-1 therapies, Foundayo is a small-molecule medicine manufactured using more established production technologies that can be more readily scaled.

Foundayo is currently under regulatory review in more than 40 countries, with Lilly targeting a full global rollout in 2027. The company is also studying the medicine for additional indications, including type 2 diabetes and obstructive sleep apnea, with further clinical data expected later in 2026.

Beyond Foundayo, the Houston manufacturing site will support the production of advanced therapeutics, including oligonucleotides, a class of medicines designed to work at the genetic level by inhibiting the production of specific proteins. These therapies represent an expanding area of pharmaceutical development, with potential applications in treating diseases closer to their underlying biological causes.

The manufacturing complex will incorporate artificial intelligence, machine learning, digitally integrated systems, and advanced data analytics to improve manufacturing operations. Digital automation will be embedded throughout the facility to streamline production processes, support quality control, and help maintain a reliable supply of medicines.

Lilly is also making a substantial investment in workforce development to support the facility’s operations. The company is providing $12.5 million to support a partnership with San Jacinto College, establishing training pathways for Houston-area residents interested in advanced chemical synthesis manufacturing careers.

The partnership will expand the college’s training equipment and facilities while preparing technicians, manufacturing operators, maintenance professionals, and other skilled workers. Lilly employees will also contribute their expertise to curriculum development and instructor preparation. The training programs will provide opportunities for individuals without previous manufacturing experience to enter the biopharmaceutical industry.

Separately, Lilly is contributing $2.5 million to the San Jacinto College Foundation to provide scholarships for eligible students. Together, the workforce development partnership and scholarship contribution represent $15 million in support for education and workforce development in the Houston region.

The Houston project is part of Lilly’s broader expansion of its American manufacturing network. Of the 10 U.S. manufacturing locations announced since 2020, five will produce active pharmaceutical ingredients. These include facilities in Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two locations in Lebanon, Indiana.

The company’s other announced projects include four facilities dedicated to injectable medicines and manufacturing devices in North Carolina, Wisconsin, and Pennsylvania, along with an advanced therapies facility in Lebanon, Indiana, focused on genetic medicines.

The expansion is intended to establish additional domestic manufacturing capacity for Lilly’s growing portfolio of medicines while supporting the development of next-generation therapies. The Houston investment will also strengthen the region’s pharmaceutical manufacturing workforce through its collaboration with San Jacinto College and create new opportunities for skilled workers throughout the greater Houston area.

KEY QUOTES:

“We are thrilled to break ground on our latest ‘medicines made in America’ site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly’s latest products from Texas to people here at home and around the world.”

David A. Ricks, Chair and CEO of Eli Lilly and Company

“When you invest in a place like Houston, you invest in its people first. This facility will run on the talent of this community, powered by our relationship with San Jacinto College. We’re hiring across the greater Houston area to help residents build careers close to home. The facility itself is being built to the highest standards for safety, quality and responsible stewardship of the environment, and every one of these jobs helps bring innovative medicines to the patients counting on them.”

Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations

“Eli Lilly’s manufacturing investment in Generation Park is a tremendous opportunity for the Houston region. San Jacinto College is proud to work with Lilly to develop the skilled workforce needed to support the growth of biopharmaceutical manufacturing. Together, we will expand industry-informed education and hands-on training pathways that prepare students and incumbent workers with the technical skills these advanced manufacturing careers require. This relationship will build a strong, sustainable talent pipeline for Lilly while creating meaningful, high-demand career opportunities across our region.”

Dr. Brenda Hellyer, Chancellor of San Jacinto College

Thank you for visiting Pulse 2.0. We work hard every day to bring leaders and decision makers like you the latest intelligence on business, finance, capital markets, deal flow, law, tech, and AI. Click here to subscribe to the Pulse 2.0 Newsletter.

Source link

Amazon and Wiwynn expand Texas manufacturing facility, creating nearly 1,000 jobs

“Amazon’s continued work with Wiwynn to bring nearly 1,000 advanced manufacturing jobs to the U.S. is exactly the type of collaboration we want to see to help strengthen the U.S. supply chain. This investment is one example of Taiwan’s commitment to invest $250 billion in advanced manufacturing into the United States.“ said Deputy United States Trade Representative, Ambassador Rick Switzer. “America’s competitive edge is reliant on investment that will onshore more of these opportunities and our administration is committed to supporting the critical infrastructure that will spur our economic growth.”

“Wiwynn’s new advanced manufacturing facility represents a major new chapter in our global manufacturing footprint and an important milestone for Amazon, Texas, and the entire U.S. supply chain,” said William Lin, president and CEO of Wiwynn. “Through our over $1.6 billion investment in the Texas facility, we are expanding our ability to address the growing demand of U.S. customers, reinforce the resilience of the global supply chain, and create high-value career opportunities as we continue to grow in partnership with the local community.”

Amazon’s data centers power the services millions of people and businesses rely on every day, from hospitals and emergency services to streaming entertainment and AI innovation. Wiwynn’s server racks are a critical part of that infrastructure, and together, these investments help fuel the U.S. economic engine. Since 2017, data center activity has grown U.S. manufacturing jobs by nearly 70% to over 200,000 jobs*.

Source link

Lonza strengthens US manufacturing with new commercial spray-drying facility

Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today plans to further strengthen its significant US presence by constructing a large-scale commercial spray-drying facility in Bend, Oregon. The investment will establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the US. Lonza will offer a full range of spray-dried dispersion (SDD) capacity to support customers across both clinical and commercial programs. Through its integrated end-to-end offering, Lonza will support the development and manufacturing of small molecules and other modalities, including biologics and mRNA.

SDD technologies are increasingly relevant in modern drug development, as the industry addresses the growing complexity of molecules and their related bioavailability challenges. The demand for SDD CDMO services has grown alongside the increasing scientific complexity of pharmaceutical pipelines, driven by the increasing prevalence of poorly soluble drug substances. Today, a significant share of molecules in the clinical pipeline requires bioavailability enhancement. The Bend expansion is intended to meet this growing market demand, with a particular focus on US demand, enabling Lonza to provide customers with an additional option to access a complete and integrated end-to-end development and manufacturing solution for SDDs.

Wolfgang Wienand, Chief Executive Officer, Lonza, said: “The investment in the Bend site reflects our conviction that the United States will remain a leading source of pharmaceutical innovation and a key market for Lonza. It also delivers on our One Lonza strategy, powered by the Lonza Engine, to invest where we can create the greatest value for our customers and, ultimately, for patients. By significantly expanding our commercial-scale spray-drying capabilities, we strengthen a technology that can fundamentally improve the delivery and bioavailability of medicines. With this, our world-class particle engineering team in Bend will be even better able to support our customers in turning their breakthrough innovations into viable products and to manufacture the medicines of tomorrow.”

Christian Seufert, Head of Advanced Synthesis, Lonza, added: “The growing number of complex drug molecules is increasing demand for advanced particle engineering technologies. With decades of expertise in spray-drying, our Bend team helps customers address formulation challenges and progress their programs efficiently. This investment expands the capacity and capabilities needed to support customers from development through commercialization.”

The new facility will be equipped with two state-of-the-art PSD-4 spray-drying units, allowing for future capacity expansions as demand continues to grow. Additional upgrades to the Bend site include supporting infrastructure for solvent handling and storage. The project also integrates energy-efficient utility and process systems and enhanced emission control technologies to reduce overall facility energy demand.

The new facility, expected to be completed in 2029, will be delivered through a significant capital investment and will initially create more than 80 new jobs, highlighting Lonza’s commitment to expanding its manufacturing footprint in the US. The expansion enhances proximity to key customers and supports more resilient, regionalized supply chains for critical therapies.

Source link

Suniva raises US$825 million for 4.5GW cell manufacturing facility

Suniva raises US$825 million for 4.5GW cell manufacturing facility – PV Tech

Skip to content

Source link

Vicente Torns announces first U.S. manufacturing facility – Peak of Ohio

A major economic development announcement has been made in West Liberty after months of work at the local and state levels.

Spanish manufacturer Vicente Torns has announced plans to establish its first U.S. operation in Logan County, bringing new investment and job opportunities to the community.

The project is also receiving support from the state through a Job Creation Tax Credit.

Vicente Torns is among 13 projects approved by the Ohio Tax Credit Authority, with the statewide projects expected to create more than 3,500 new jobs and bring more than $1.1 billion in investment.

The company is expected to create 108 full-time jobs, generating more than $7.1 million in new annual payroll by the end of 2030.

Vicente Torns is a third-generation, family-owned company with more than 100 years of operating history.

The company manufactures copper and aluminum cables and wires used in the energy, automotive, and transportation industries.

As part of the project, Vicente Torns plans to acquire an existing building in West Liberty, renovate and expand it, and add new equipment.

The expansion will allow the company to manufacture conductors used in electric transformers.

The Ohio Tax Credit Authority approved a 1.427-percent, eight-year Job Creation Tax Credit for the project.

Governor Mike DeWine, Lieutenant Governor Jim Tressel and Ohio Department of Development Director Lydia Mihalik announced the approvals Monday.

Statewide, the 13 projects are expected to create 3,553 new jobs, retain another 907 jobs, and generate nearly $310 million in new payroll.

The projects span several industries, including manufacturing, aerospace, defense, technology, and engineering.

Here are the details in the official announcement:

“Vicente Torns Ohio Corp., an international manufacturer of copper and aluminum cables and wires, will establish its first U.S. manufacturing facility in West Liberty. The company will invest $21 million at 600 N. Detroit St. and create 108 new jobs representing $7.1 million in new annual payroll.

The West Liberty operation will produce copper and aluminum wires used in electric transformers. The project will establish a U.S. manufacturing base for Vicente Torns as the company expands its presence in North America and serves growing demand from the energy industry.

“Establishing our first manufacturing operation in the United States marks an important step in the continued growth of Vicente Torns. Within four years, we expect the U.S. market to account for 15 percent of the group’s total revenue,” said Vicente Torns, CEO of Vicente Torns. “West Liberty provides a strong foundation to serve our customers, build a skilled local workforce and expand our production capabilities in North America. We appreciate the partnership and support that helped bring this investment to the Columbus Region.”

With more than 100 years of manufacturing experience, Vicente Torns operates facilities in Spain, Slovakia, Italy, Morocco, India and France. The company serves customers across different sectors, especially is energy, particularly transformers, high-voltage motors, and generators, and, to a lesser extent, electric vehicles and railways.

“Vicente Torns’ decision to establish its first U.S. manufacturing facility in West Liberty is a major vote of confidence in our community and our workforce,” said West Liberty Mayor Brad Hudson. “This investment will create more than 100 jobs and bring a respected international manufacturer with more than a century of experience to Logan County. We look forward to supporting the company’s success here.”

Pending local approval, the project represents a significant foreign direct investment in the Columbus Region and adds to the Region’s growing base of international manufacturers. Vicente Torns’ selection of West Liberty also creates new manufacturing capacity supporting equipment essential to the nation’s electric infrastructure.

“The Columbus Region has become a strong entry point for global manufacturers establishing U.S. operations,” said Jonas Peterson, chief economic development officer and president of One Columbus. “Our central location provides efficient access to major North American markets. Our manufacturing base connects companies with experienced workers and established industrial partners. Communities such as West Liberty offer the capacity and support needed for long-term growth. Vicente Torns’ decision reflects the strength of that regional proposition.”

Vicente Torns selected Logan County for its first U.S. manufacturing operation as rising energy demand drives greater need for the copper and aluminum wire used in electric transformers. The decision reflects the strength of the area’s manufacturing workforce and the Columbus Region’s strategic access to customers across North America.

“Ohio continues to win global manufacturers because we deliver what they actually need: access to customers, resilient supply chains, and the ability to scale fast from the center of the North American market,” said JobsOhio President and CEO J.P. Nauseef. “Vicente Torns’ investment is proof our strategy to attract global companies critical to the nation’s energy infrastructure is working.”

Source link

Apple opens Advanced Manufacturing Center at massive Houston facility

Cupertino, California-based Apple Inc. unveiled its Advanced Manufacturing Center in the Houston area last week, marking the completion of the second of three facilities the tech giant plans to launch in the city by the end of this year.

The 20,000-square-foot training center will welcome small- and medium-sized businesses for free training and educational sessions to “help accelerate smart manufacturing across America,” according to a release from Apple. Apple opened a similar Apple Manufacturing Academy in Detroit last year.

The AMC is part of Apple’s 500,000-square-foot site in northwest Harris County. It also features a massive manufacturing site for Apple’s advanced AI servers and Mac mini. The facility was originally slated to open in 2026, but Apple began producing its advanced AI servers ahead of schedule in 2025.

The company said it plans to begin manufacturing its Mac mini at the site this year. The move will bring production of the compact desktop computer to the U.S. for the first time.

“In less than nine months, we have invested hundreds of millions of dollars into this Houston facility. We stood up a factory, started production, and shipped the first advanced AI servers off the line. Today, we’re thrilled to open our new Advanced Manufacturing Center, a place where businesses, workers, and students can learn the same innovative processes that we use to make Apple’s most groundbreaking products. And we’re pleased to begin Mac mini production later this year,” Tim Cook, Apple’s CEO, said in the news release. “We believe in American workers and American ingenuity, and we are moving at an incredible pace because we want to build more than great products. We want to build the future of American manufacturing.”

Apple’s Houston expansion is part of a $600 billion commitment the company made to the U.S. in 2025.

The company originally announced plans in February 2025 to open a 250,000-square-foot Houston factory, but doubled the facility’s planned size about a year later. Apple has reported that the factory will employ thousands of workers.

“Houston is grateful to Apple for this significant investment in our city. The Advanced Manufacturing Center will create local jobs and will continue improving the quality of life of Houston residents,” Houston Mayor John Whitmire added in the release. “The AMC also recognizes our city as a growing technology hub and solidifies Houston’s leadership in the manufacturing sector of the United States.”

The opening comes on the heels of New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. officially naming Houston home of its new $2.3 billion, state-of-the-art manufacturing site. Read more here.

Source link